Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma (vol 15, pg 737, 2015)

被引：3
|
作者：
Richardson, P. G. [1 ]
Laubach, J. P. [1 ]
Lonial, S. [1 ]
机构：
[1] Univ Navarra Clin, IDISNA, CIMA, Pamplona, Spain
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 09期
关键词：
D O I：
10.1586/14737140.2015.1071726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1121 / 1121
页数：1
相关论文
共 50 条
  • [21] Treatment of relapsed and refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    BLOOD RESEARCH, 2020, 55 : 43 - 53
  • [22] EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
    Tzogani, Kyriaki
    van Hennik, Paula
    Walsh, Ita
    De Graeff, Pieter
    Folin, Annika
    Sjoberg, Jan
    Salmonson, Tomas
    Bergh, Jonas
    Laane, Edward
    Ludwig, Heinz
    Gisselbrecht, Christian
    Pignatti, Francesco
    ONCOLOGIST, 2018, 23 (05): : 631 - 636
  • [23] Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
    Moore, Donald C.
    Arnall, Justin R.
    Harvey, R. Donald
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 613 - 622
  • [24] PANOBINOSTAT, A PAN-HISTONE DEACETYLASE INHIBITOR: RATIONALE FOR AND APPLICATION TO TREATMENT OF MULTIPLE MYELOMA
    Cheng, T.
    Grasse, L.
    Shah, J.
    Chandra, J.
    DRUGS OF TODAY, 2015, 51 (08) : 491 - 504
  • [25] Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
    Avineesh Singh
    Vijay K. Patel
    Deepak K. Jain
    Preeti Patel
    Harish Rajak
    Oncology and Therapy, 2016, 4 (1) : 73 - 89
  • [26] Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma (vol 42, pg 2702, 2024)
    Bumma, Naresh
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans C.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Pianko, Matthew J.
    Ye, Jing Christine
    Wu, Ka Lung
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez-Lopez, Joaquin
    Cassady, Kaniel
    DeVeaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Yancopoulos, George D.
    Sirulnik, L. Andres
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Dhodapkar, Madhav, V
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33) : 4001 - 4001
  • [27] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Gregory, Tara K.
    Matous, Jeffrey
    Hart, Lowell L.
    Owera, Rami
    Mace, Joseph Ronald
    Essell, James H.
    Flinn, Ian
    Faber, Edward Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
    Singh, Avineesh
    Patel, Vijay K.
    Jain, Deepak K.
    Patel, Preeti
    Rajak, Harish
    ONCOLOGY AND THERAPY, 2016, 4 (01) : 73 - 89
  • [29] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    Laubach, J. P.
    Mahindra, A.
    Mitsiades, C. S.
    Schlossman, R. L.
    Munshi, N. C.
    Ghobrial, I. M.
    Carreau, N.
    Hideshima, T.
    Anderson, K. C.
    Richardson, P. G.
    LEUKEMIA, 2009, 23 (12) : 2222 - 2232
  • [30] Novel treatment approaches for patients with relapsed and refractory multiple myeloma
    Sinha R.
    Lonial S.
    Current Treatment Options in Oncology, 2006, 7 (3) : 246 - 257
12345